Table 6.

Significant GSTM1 null moderation of the effects of tocolytic use during pregnancy on ASD development (with parental age, neonatal jaundice, prematurity, RDS, and other GST genotypes as covariates; *p < 0.05; **p < 0.01).

Predictor to outcome	Interaction effect of GSTM1 genotype with use of tocolytics during pregnancy B (LLCI-ULCI)	GSTM1-active conditional effect B (LLCI-ULCI)	GSTM1-null conditional effect B (LLCI-ULCI)
Use of tocolytics during pregnancy to ASD status	−2.792 (−5.208 to −0.376)*	−0.598 (−0.532 to 1.412)	2.732 (0.860 to 4.604)**